# Study of SC-102 in Patients With Advanced Solid Tumors

Source: https://onco.cc/trials/nct06710158/  
OnCo record `nct06710158` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of SC-102 run by Tianjin ConjuStar Biologics Co., Ltd., now recruiting.

## Summary

Study of SC-102 in Patients With Advanced Solid Tumors is a phase 1 interventional study registered as NCT06710158 by Tianjin ConjuStar Biologics Co., Ltd., with 120 participants planned, started 2024-12-05. Conditions recorded: Advanced Solid Cancers. Interventions recorded: SC-102.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06710158
- Phase: 1
- Setting: Phase Ⅰ Study to Evaluate the Safety/Tolerability, Pharmacokinetics, and Efficacy of SC-102 in Subjects With Advanced or Metastatic Solid Tumors That Express EphA2
- Sponsor: Tianjin ConjuStar Biologics Co., Ltd.
- Enrolled: 120

## Sources

- ClinicalTrials.gov NCT06710158: https://clinicaltrials.gov/study/NCT06710158

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [SC-102](https://onco.cc/drugs/sc-102/)
- companies: [ConjuStar Biologics](https://onco.cc/companies/conjustar-biologics/)

---
JSON: https://onco.cc/api/v1/entities/nct06710158.json